KR20240027761A - 인항원을 포함하는 접합체 및 요법에서의 이의 용도 - Google Patents

인항원을 포함하는 접합체 및 요법에서의 이의 용도 Download PDF

Info

Publication number
KR20240027761A
KR20240027761A KR1020247003259A KR20247003259A KR20240027761A KR 20240027761 A KR20240027761 A KR 20240027761A KR 1020247003259 A KR1020247003259 A KR 1020247003259A KR 20247003259 A KR20247003259 A KR 20247003259A KR 20240027761 A KR20240027761 A KR 20240027761A
Authority
KR
South Korea
Prior art keywords
moiety
linker
cells
mmol
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247003259A
Other languages
English (en)
Korean (ko)
Inventor
로널드 크리스티안 엘게르스마
데니스 크리스티안 요하네스 왈보어
Original Assignee
비온디스 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비온디스 비.브이. filed Critical 비온디스 비.브이.
Publication of KR20240027761A publication Critical patent/KR20240027761A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247003259A 2021-06-28 2022-06-28 인항원을 포함하는 접합체 및 요법에서의 이의 용도 Pending KR20240027761A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21182160 2021-06-28
EP21182160.8 2021-06-28
PCT/EP2022/067693 WO2023275025A1 (en) 2021-06-28 2022-06-28 Conjugates comprising phosphoantigens and their use in therapy

Publications (1)

Publication Number Publication Date
KR20240027761A true KR20240027761A (ko) 2024-03-04

Family

ID=76695639

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003259A Pending KR20240027761A (ko) 2021-06-28 2022-06-28 인항원을 포함하는 접합체 및 요법에서의 이의 용도

Country Status (12)

Country Link
US (1) US20240261426A1 (https=)
EP (1) EP4362982A1 (https=)
JP (1) JP2024524363A (https=)
KR (1) KR20240027761A (https=)
CN (1) CN117794581A (https=)
AU (1) AU2022302784A1 (https=)
BR (1) BR112023026735A2 (https=)
CA (1) CA3223936A1 (https=)
CL (1) CL2023003905A1 (https=)
IL (1) IL309249A (https=)
MX (1) MX2023014899A (https=)
WO (1) WO2023275025A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120379696A (zh) 2022-12-22 2025-07-25 拜奥迪斯私人有限公司 包含磷酸抗原的新的接头药物、新的缀合物及其在治疗中的用途
WO2026080697A1 (en) * 2024-10-09 2026-04-16 Sutro Biopharma, Inc. Antibody conjugates with high payload to antibody ratios, compositions comprising the same, and methods of their use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
FI115001B (fi) 2003-07-11 2005-02-15 Metso Paper Inc Menetelmä ja sovitelma rullan päätylapun sijainnin mittaamiseksi
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
ATE419008T1 (de) * 2004-04-26 2009-01-15 Innate Pharma Adjuvante zusammensetzung und anwendungsverfahren dafür
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
EP1948195A2 (en) * 2005-11-17 2008-07-30 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
WO2008059052A1 (en) * 2006-11-17 2008-05-22 Innate Pharma Improved methods of using phosphoantigen for the treatment of cancer
WO2009152440A1 (en) * 2008-06-13 2009-12-17 Cedars-Sinai Medical Center Small molecule ligand-drug conjugates for targeted cancer therapy
WO2010049438A2 (en) * 2008-10-30 2010-05-06 Innate Pharma Improved methods of using phosphoantigens for the treatment of diseases
ES2647317T3 (es) 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
PT3056203T (pt) 2010-04-21 2018-02-15 Syntarga Bv Conjugados de análogos de cc-1065 e ligantes bifuncionais
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
CN110947002A (zh) * 2012-05-01 2020-04-03 约翰霍普金斯大学 治疗或预防骨关节炎的组合物和方法
ES2773710T3 (es) 2012-10-11 2020-07-14 Daiichi Sankyo Co Ltd Enlazadores para conjugados de anticuerpo - fármaco
SG11201609372UA (en) 2014-05-22 2016-12-29 Synthon Biopharmaceuticals Bv Site-specific conjugation of linker drugs to antibodies and resulting adcs
EP3368092B9 (en) 2015-10-29 2020-07-29 Novartis AG Antibody conjugates comprising toll-like receptor agonist
CA3026139C (en) 2016-02-12 2023-09-12 Synthon Biopharmaceuticals B.V. Selective reduction of cysteine-engineered antibodies
US11419944B2 (en) 2016-10-11 2022-08-23 Byondis B.V. Non-linear self-immolative linkers and conjugates thereof
US11696958B2 (en) 2017-05-23 2023-07-11 Byondis B.V. Dual conjugation process for preparing antibody-drug conjugates
WO2019182904A1 (en) 2018-03-19 2019-09-26 University Of Iowa Research Foundation Phosphonamidate butyrophilin ligands
GB201810965D0 (en) 2018-07-04 2018-08-15 Univ College Cardiff Consultants Ltd Phosphoantigen prodrug compounds
CA3110510A1 (en) 2018-08-29 2020-03-05 Bolt Biotherapeutics, Inc. Immunoconjugates targeting egfr

Also Published As

Publication number Publication date
CL2023003905A1 (es) 2024-08-02
CA3223936A1 (en) 2023-01-05
MX2023014899A (es) 2024-04-29
US20240261426A1 (en) 2024-08-08
AU2022302784A1 (en) 2023-12-21
BR112023026735A2 (pt) 2024-03-12
WO2023275025A1 (en) 2023-01-05
EP4362982A1 (en) 2024-05-08
JP2024524363A (ja) 2024-07-05
IL309249A (en) 2024-02-01
CN117794581A (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
AU2017377233B2 (en) Combination of antibody-drug conjugate and immune checkpoint inhibitor
US10246510B2 (en) KIR3DL2 binding agents
EP4161582A2 (en) Antibody-drug conjugates containing an anti-mesothelin antibody and uses thereof
US20230117205A1 (en) B7-h4 antibody-drug conjugates for the treatment of cancer
US20230330248A1 (en) Antibody-drug conjugate including novel cyclic dinucleotide derivative
CN110898226B (zh) Iap抑制剂与免疫检查点分子调节剂的组合用于治疗癌症的方法
JP2018509908A (ja) Ｃｄ４８抗体及びその複合体
CA2945318A1 (en) Tubulysin derivatives
WO2022057942A1 (zh) 一种药物组合及其应用
AU2005238298A1 (en) Compositions and methods for enhancing NK cell activity
KR20240027761A (ko) 인항원을 포함하는 접합체 및 요법에서의 이의 용도
WO2025083071A2 (en) Antibody-drug conjugates
CA3183993A1 (en) Anti-asgr1 antibody conjugates and uses thereof
KR20260020459A (ko) 항-ceacam5 항체-약물 접합체, 항-pd1/pd-l1 항체 및 항-ctla4 항체를 함유하는 항종양 조합물
KR20250121443A (ko) 인 항원을 포함하는 신규한 링커 약물, 신규한 접합체 및 치료에서의 이들의 용도
CN104861063A (zh) 靶向her2阳性肿瘤的化合物和组合物
HK40107728A (zh) 用於治疗癌症的b7-h4抗体-药物缀合物
KR20260021654A (ko) Ctla4를 표적화하는 약물 접합체, 이를 포함하는 제품, 및 이의 치료적 용도
WO2026019375A1 (en) B7h3-binding molecules
HK40015605B (en) Method for treating cancer by combination of iap inhibitor and modulator of immune checkpoint molecule
EA045378B1 (ru) Усиление эффекта от высвобождения аденозинтрифосфата (атф)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240126

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250627

Comment text: Request for Examination of Application